The Nature Communications publication surveyed the thermostability of thousands of pMHC interactions simultaneously by mass spectrometry. The data enabled Evaxion to train its unique artificial intelligence platform to select epitopes for optimal immunogenicity, which may lead to better patient-specific cancer immunotherapies.

Evaxion's immune-oncology Pioneer platform identifies peptide ligands of MHC molecules using mass spectrometry to generate large databases of peptides to improve prediction of peptide binding and immunogenicity using artificial intelligence-based approaches. The new methodology used to generate the thermostability data can be incorporated into the platform for identification of new neoepitopes (tumor-specific mutations).

The company believes the mass spectrometry approach will apply to any cells bearing MHC or MHC-like molecules and therefore has applications beyond cancer, including areas such as infectious diseases.

Cue Biopharma, Merck expand Immuno-STAT collaboration
Cue Biopharma has extended the terms of its research collaboration and license agreement with Merck toward developing new clinical candidates for the...

COVID-19 vaccine based on peptide nanofibers shows promise
A new technology platform using self-assembling peptide nanofibers tagged with antibodies can be an effective SARS-CoV-2 vaccine, according to a proof-of-concept...

Researchers discuss progress toward personalized cancer vaccines
Highly targeted and adaptable platforms allow researchers to develop cancer vaccines for a multitude of different cancer types and even create personalized...